← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Melanotan I × PT-141 × 2 of 4 selected View comparison

Melanotan I

α-MSH analogue

Remove
VS

PT-141

Cyclic melanocortin receptor agonist

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target Melanotan IPT-141
✓ —
— ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Melanotan I → Predominantly MC1R
PT-141 → Central melanocortin signalling associated with sexual-response research

What These Compounds Share

Shared research line

All selected compounds are catalogued under Enhance.

Shared pathway tags
Melanocortin

Key Differences

Melanotan I MC1R is a direct target of Melanotan I that none of the other selected compounds share. A more MC1R-focused profile than Melanotan II.
PT-141 MELANOCORTIN is a direct target of PT-141 that none of the other selected compounds share. A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.

Compound Detail

Melanotan I
What is it?
A lab-made peptide focused specifically on skin pigmentation signalling.
What are people researching/using it for?
Studied for skin tanning and photoprotection.
Other uses being trialed
General pigmentation-disorder research
Worth knowing
"Melanotan-I" is the original research name for [Nle4,D-Phe7]-alpha-MSH -- the same amino acid sequence later developed by Clinuvel into afamelanotide (brand name Scenesse), a slow-release subcutaneous implant. These are the same active peptide, not two related-but-separate molecules; they differ in formulation and delivery method (an immediate peptide vial here vs. a controlled-release implant for the approved drug), not in chemical identity. This confirms the molecule-level identity from the literature -- it does not by itself confirm that any specific Vital Edge batch matches this sequence/purity without its own product-specific lab verification (the same standard applied to TB-500 on this site).

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
An α-MSH analogue with a predominantly MC1R-focused profile, promoting melanogenic signalling.
Synthetic peptide · Synthetic analogue
Primary Targets & Biological System
Melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
An analogue of α-MSH that is predominantly selective for MC1R, the melanocortin receptor found mainly on melanocytes (pigment-producing skin cells). Activating MC1R shifts melanocyte pigment production toward eumelanin (the darker pigment) and away from pheomelanin, the basis for its research use in photoprotection and pigmentation studies. This relative MC1R selectivity is what mechanistically distinguishes it from Melanotan II's broader melanocortin-receptor activity.
Research Areas
MelanogenesisPigmentationPhotobiologyMC1R signalling
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Beta-phase half-life approximately 0.8-1.7 hours (IV/SC)
Measured directly in a 3-participant human PK trial comparing IV, oral and SC administration -- no detectable drug after oral dosing (not orally bioavailable); this is a very small sample.
Research Routes
Subcutaneous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A more MC1R-focused profile than Melanotan II.
Considerations
Research Limitations
"Melanotan-I" is the original research name for [Nle4,D-Phe7]-alpha-MSH -- the same amino acid sequence later developed by Clinuvel into afamelanotide (brand name Scenesse), a slow-release subcutaneous implant. These are the same active peptide, not two related-but-separate molecules; they differ in formulation and delivery method (an immediate peptide vial here vs. a controlled-release implant for the approved drug), not in chemical identity. This confirms the molecule-level identity from the literature -- it does not by itself confirm that any specific Vital Edge batch matches this sequence/purity without its own product-specific lab verification (the same standard applied to TB-500 on this site).
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Erythropoietic protoporphyria (EPP)
Afamelanotide (brand name Scenesse) is FDA-approved (since 2019) to increase pain-free light tolerance in EPP, a rare photosensitivity disorder. Afamelanotide is the same [Nle4,D-Phe7]-alpha-MSH sequence historically called Melanotan-I, delivered via a slow-release implant rather than as a standard peptide preparation -- so this is a genuine approved use for this molecule, in that specific approved delivery form. It is not an approval for Melanotan-I as typically sold/administered in research contexts.
Vitiligo
MC1R-pathway agonists have been researched for repigmentation in vitiligo, alongside UV-based therapy. Research on Melanotan I specifically for this purpose is limited.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Melanotan I · A$54.95 A$69.95
Browse products →
View Research Sources (1) →
Skin pigmentation and pharmacokinetics of melanotan-I in humans
Biopharmaceutics & Drug Disposition, 1997 · Human Human · 3 male volunteers · IV, oral and SC compared · PMID 9113347

The paper itself equates "[Nle4-D-Phe7]-alpha-MSH(4-13)" directly with "melanotan-I (MT-I)" -- confirming this is the literature name for the same sequence later marketed as afamelanotide/Scenesse. No detectable drug after oral dosing (not orally bioavailable). SC fully bioavailable vs IV; beta-phase half-life 0.8-1.7h; clearance 0.12-0.19 L/kg/h. Noticeable tanning after IV/SC dosing, peaking at 1 week, still present 3 weeks post-regimen. Very small sample (n=3).

Supports: human_half_life, canonical_name, research_limitations

PT-141
What is it?
A lab-made peptide that acts on brain signalling related to sexual response.
What are people researching/using it for?
Approved and studied for sexual desire/arousal research.
Other uses being trialed
General central-nervous-system melanocortin research
Worth knowing
Mechanism is central (CNS melanocortin signalling), not a vascular mechanism analogous to PDE5 inhibitors. Regulatory PK data below apply specifically to bremelanotide -- only reliable if the compared material's chemical identity is equivalent to bremelanotide.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.
Cyclic heptapeptide · 7 amino acids · Synthetic analogue
Also known as: Bremelanotide
Primary Targets & Biological System
Central melanocortin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Bremelanotide activates melanocortin receptors in the central nervous system -- research has particularly implicated MC4R -- rather than acting on the vascular system the way PDE5 inhibitors (a different, more commonly known class of sexual-response compound) do. This central mechanism is why its effects are studied in relation to sexual desire/arousal pathways in the brain rather than blood flow to peripheral tissue, a meaningful distinction worth keeping separate from vascular-mechanism compounds when comparing research on sexual response.
Research Areas
Sexual response researchCNS melanocortin signalling
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Approximately 2.7 hours
FDA prescribing information (Vyleesi/bremelanotide): median Tmax ~1 hour, terminal half-life ~2.7 hours, subcutaneous bioavailability ~100%, plasma protein binding ~21%.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
A melanocortin-derived compound developed around central sexual-response signalling rather than primarily pigmentation.
Considerations
Research Limitations
Mechanism is central (CNS melanocortin signalling), not a vascular mechanism analogous to PDE5 inhibitors. Regulatory PK data below apply specifically to bremelanotide -- only reliable if the compared material's chemical identity is equivalent to bremelanotide.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Male sexual response
Bremelanotide's FDA approval (as Vyleesi) is specifically for hypoactive sexual desire disorder in premenopausal women; its central melanocortin mechanism has also been investigated in male sexual-response research, but this is outside its approved indication.
Appetite / obesity research
Because it shares the broader melanocortin pathway with appetite-related receptors, PT-141 has been studied in early-stage appetite research -- a secondary, less-characterised research direction relative to its sexual-response work.
Availability & Sources
Current Vital Edge Testing
Batch 2 · tested Oct 2026 · 99.979% purity, 10.06mg content Purity/ID report
Available As (Vital Edge Science)
PT-141 · A$54.95 A$69.95
Browse products →
View Research Sources (1) →
Vyleesi (bremelanotide) Prescribing Information
FDA Prescribing Information — Vyleesi · Regulatory document Human

Median Tmax ~1h, terminal half-life ~2.7h, SC bioavailability ~100%, protein binding ~21%. Applies to bremelanotide specifically.

Supports: human_half_life, research_routes

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.